Tony Mok

Tony Mok

UNVERIFIED PROFILE

Are you Tony Mok?   Register this Author

Register author
Tony Mok

Tony Mok

Publications by authors named "Tony Mok"

Are you Tony Mok?   Register this Author

100Publications

4510Reads

43Profile Views

Is the LENT Score Already Outdated?

Respiration 2018 26;96(4):303-304. Epub 2018 Jul 26.

Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491678DOI Listing
September 2019

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.

Clin Cancer Res 2019 Aug 25;25(16):4881-4887. Epub 2019 Mar 25.

Airway Research Center North in the German Center for Lung Research (DZL), Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1894DOI Listing
August 2019

Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.

Future Oncol 2019 Aug 17;15(24):2795-2805. Epub 2019 Jul 17.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0299DOI Listing
August 2019

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.

J Thorac Oncol 2019 Jul 9;14(7):1213-1222. Epub 2019 Apr 9.

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, the Chinese University of Hong Kong, Hong Kong, China; Li Ka-Shing Institute of Health Sciences, Sir Y.K. Pao Cancer Center, the Chinese University of Hong Kong, Hong Kong, China; Institute of Digestive Disease, State Key Laboratory of Digestive Disease, the Chinese University of Hong Kong, Hong Kong, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.021DOI Listing
July 2019

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.

Future Oncol 2019 Jul 25;15(20):2371-2383. Epub 2019 Jun 25.

Cancer Care Centre, St George Hospital, Kogarah, Sydney, New South Wales 2217, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0105DOI Listing
July 2019

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

Drugs 2019 Jun;79(8):823-831

Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-019-01115-yDOI Listing
June 2019

Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Future Oncol 2019 May 6;15(13):1481-1491. Epub 2019 Mar 6.

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0944DOI Listing
May 2019

How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.

Ann Oncol 2019 Mar 26. Epub 2019 Mar 26.

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and Parker Center for Cancer Immunotherapy, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz109DOI Listing
March 2019

What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:196-205. Epub 2019 May 17.

4 Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_242209DOI Listing
January 2019

Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma.

J Thorac Cardiovasc Surg 2018 12 2;156(6):2310-2318.e2. Epub 2018 Aug 2.

Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2018.07.054DOI Listing
December 2018

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.

Theranostics 2018 1;8(1):61-77. Epub 2018 Jan 1.

Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.20893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743460PMC
November 2018

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

Cancer Res 2018 11 31;78(22):6486-6496. Epub 2018 Aug 31.

State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-1814DOI Listing
November 2018

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 10 14;13(10):1539-1548. Epub 2018 Aug 14.

Department of Clinical Oncology, State Laboratory of South China, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.06.012DOI Listing
October 2018

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.

Clin Lung Cancer 2018 09 7;19(5):e601-e608. Epub 2018 May 7.

Department of Clinical Oncology, State Key Laboratory of Oncology of South China, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183010
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.04.022DOI Listing
September 2018

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

J Clin Oncol 2018 09 30;36(26):2702-2709. Epub 2018 Jul 30.

Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Hye Ryun Kim, Yonsei University College of Medicine, Seoul; Ji-Youn Han, National Cancer Center, Goyang, Republic of Korea; Marina Chiara Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Nobuyuki Katakami, Institute of Biomedical Research and Innovation, Kobe, Japan; Rachel Hodge, Paramjit Kaur, Andrew P. Brown, and Dana Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Vassiliki A. Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9363DOI Listing
September 2018

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Curr Treat Options Oncol 2018 09 29;19(11):58. Epub 2018 Sep 29.

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong SAR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-018-0570-9DOI Listing
September 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.4794DOI Listing
August 2018

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 08 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018

3D Randomized Connection Network with Graph-based Label Inference.

IEEE Trans Image Process 2018 08 23;27(8):3883-3892. Epub 2018 Apr 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1109/TIP.2018.2829263DOI Listing
August 2018

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Cancer Res Treat 2018 Jul 6;50(3):691-700. Epub 2017 Jul 6.

State Key Laboratory of South China, Hong Kong Cancer Institute and The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2017.280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056984PMC
July 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

J Thorac Oncol 2018 06 23;13(6):792-800. Epub 2018 Mar 23.

Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.010DOI Listing
June 2018

Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

J Clin Oncol 2018 06 7;36(18):1853-1860. Epub 2018 May 7.

Chee Khoon Lee, St George Hospital, Kogarah, New South Wales, Australia; Silvia Novello, University of Turin, Turin, Italy; Anna Rydén, AstraZeneca Gothenburg, Mölndal, Sweden; Helen Mann, AstraZeneca R&D, Cambridge, United Kingdom; and Tony Mok, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.2293
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.2293DOI Listing
June 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 01 6;19(1):27-34. Epub 2017 Jul 6.

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.013DOI Listing
January 2018

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Lung Cancer 2018 01 13;115:12-20. Epub 2017 Nov 13.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.009DOI Listing
January 2018

Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.

Lancet Oncol 2018 01;19(1):e5

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30924-5DOI Listing
January 2018

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI.

Oncol Lett 2018 Jan 9;15(1):901-907. Epub 2017 Nov 9.

Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, SAR, P.R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2017.7377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772989PMC
January 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

De-novo and acquired resistance to immune checkpoint targeting.

Lancet Oncol 2017 12;18(12):e731-e741

Department of Haematology-Oncology, National University Cancer Institute, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30607-1DOI Listing
December 2017

Blood-based tumor biomarkers in lung cancer for detection and treatment.

Transl Lung Cancer Res 2017 Dec;6(6):648-660

Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2017.09.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709129PMC
December 2017

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Cancer 2017 Oct 22;123(20):3977-3985. Epub 2017 Jun 22.

Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30825DOI Listing
October 2017

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 10 24;12(10):1536-1543. Epub 2017 Jul 24.

Department of Thoracic Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173061
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.07.015DOI Listing
October 2017

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2017 08 6;377(9):829-838. Epub 2017 Jun 6.

From Lausanne University Hospital, Lausanne (S.P.), and F. Hoffmann-La Roche, Basel (A.Z., E.M., S. Golding, B.B., J.N.) - both in Switzerland; University of Colorado, Denver (D.R.C.); Massachusetts General Hospital, Boston (A.T.S.); University of Michigan, Ann Arbor (S. Gadgeel); Samsung Medical Center, Sungkyunkwan University School of Medicine (J.S.A.), and Seoul National University Hospital (D.-W.K.) - both in Seoul, South Korea; Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.); Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France (M.P.); Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (R.D.); Catalan Institute of Oncology, Barcelona (R.R.); Roche Innovation Center, New York (P.N.M.); and State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1704795DOI Listing
August 2017

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.

J Thorac Oncol 2017 05 20;12(5):890-896. Epub 2017 Jan 20.

Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.012DOI Listing
May 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Osimertinib in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 05;376(20):1993-4

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1703339DOI Listing
May 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma.

Liver Int 2017 02 29;37(2):280-289. Epub 2016 Aug 29.

State Key Laboratory in Oncology of South China, Hong Kong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.13218DOI Listing
February 2017

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

J Thorac Oncol 2017 02 17;12(2):403-407. Epub 2016 Oct 17.

Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei City, Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.007DOI Listing
February 2017

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

J Clin Oncol 2017 Feb 12;35(4):412-420. Epub 2016 Dec 12.

David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD; Kenneth O'Byrne, Queensland University of Technology, Brisbane, Queensland, Australia; Luis Paz-Ares, Hospital Universitario Doce de Octubre and Centro Nacional de Investigaciones Oncológicas, Madrid, Spain; Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, and Virginia E. Paton, Genentech, South San Francisco, CA; and Tony Mok, Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2160DOI Listing
February 2017

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 02 6;376(7):629-640. Epub 2016 Dec 6.

From the State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong (T.S.M.), the Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), and the Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing (Y.H.) - all in China; the Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, (M.-J.A.), and the Yonsei Cancer Center, Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine (H.R.K.), Seoul, South Korea; the Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (M.C.G.); the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.); the Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto (F.A.S.); the Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan (H.A.); the Department of Thoracic Oncology, the Netherlands Cancer Institute, Plesmanlaan, Amsterdam (W.S.M.E.T.); the Clinical Research Unit, Division of Cancer Services, St. George Hospital, Kogarah, NSW, Australia (C.K.L.); the Department of Hematology-Oncology, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany (M.S.); AstraZeneca, Cambridge, United Kingdom (A.T., H.M., M.M., S.G.); and the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (V.A.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6762027PMC
February 2017

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Clin Lung Cancer 2017 01 27;18(1):5-12. Epub 2016 Jun 27.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361177PMC
January 2017

Is there significance in identification of non-predominant micropapillary or solid components in early-stage lung adenocarcinoma?

Interact Cardiovasc Thorac Surg 2017 01 5;24(1):121-125. Epub 2016 Sep 5.

Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/icvts/ivw283DOI Listing
January 2017

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.

J Thorac Oncol 2016 10 21;11(10):1736-44. Epub 2016 Jul 21.

Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.038DOI Listing
October 2016

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5888DOI Listing
August 2016

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Clin Cancer Res 2016 06 4;22(12):3048-56. Epub 2016 Feb 4.

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong. State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong. Li Ka-Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2061DOI Listing
June 2016

Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.

Sci Rep 2016 05 26;6:26591. Epub 2016 May 26.

Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep26591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880909PMC
May 2016

Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

Lancet 2016 Apr 19;387(10027):1488-1490. Epub 2015 Dec 19.

Department of Clinical Oncology, Faculty of Medicine, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)01308-2DOI Listing
April 2016

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 Mar 25;34(9):953-62. Epub 2016 Jan 25.

Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8824DOI Listing
March 2016

Special Issue on Global Cancer Medicine.

J Clin Oncol 2016 01 17;34(1):1-2. Epub 2015 Nov 17.

The Chinese University of Hong Kong, Hong Kong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.6067DOI Listing
January 2016

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.

J Clin Oncol 2016 Jan 17;34(1):91-101. Epub 2015 Nov 17.

Daniel S.W. Tan, National Cancer Centre Singapore and Genome Institute of Singapore, Singapore; Tony S.K. Mok, The Chinese University of Hong Kong, Sir Y. K. Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong, China; and Timothy R. Rebbeck, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.0096DOI Listing
January 2016

Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.

J Thorac Oncol 2015 Sep;10(9):1292-1300

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong; State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Shatin, Hong Kong; Li Ka-Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000620DOI Listing
September 2015

Novel targeted agents for the treatment of lung cancer in China.

Cancer 2015 Sep;121 Suppl 17:3089-96

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.29522
Publisher Site
http://dx.doi.org/10.1002/cncr.29522DOI Listing
September 2015

Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non-small cell lung cancer.

Cancer 2015 Sep;121 Suppl 17:3130-45

Department of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29547DOI Listing
September 2015